SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours
2016 ◽
Vol 27
◽
pp. vi99
◽
J. Baselga
◽
J. Cortes Castan
◽
M. De Laurentiis
◽
V. Dieras
◽
N. Harbeck
◽
...
2016 ◽
Vol 34
(15_suppl)
◽
pp. TPS617-TPS617
◽
Jose Baselga
◽
Javier Cortes
◽
Michele De Laurentiis
◽
Veronique Dieras
◽
Nadia Harbeck
◽
...
J Baselga
◽
J Cortés
◽
M De Laurentiis
◽
S Dent
◽
V Diéras
◽
...
J Baselga
◽
J Cortés
◽
M De Laurentiis
◽
V Diéras
◽
N Harbeck
◽
...
A Di Leo
◽
C Germa
◽
D Weber
◽
E Di Tomaso
◽
B Dharan
◽
...
MJ Ellis
◽
M Prahladan
◽
NL Green
◽
E Mari
◽
JFR Robertson
2020 ◽
Vol 31
◽
pp. S391-S392
N. Turner
◽
K. Jhaveri
◽
K. Kalinsky
◽
S. Loibl
◽
S. Loi
◽
...
J Baselga
◽
M Campone
◽
J Cortes
◽
H Iwata
◽
M de Laurentiis
◽
...
A Di Leo
◽
K Seok Lee
◽
E Ciruelos
◽
P Lønning
◽
W Janni
◽
...
Nicolas Turner
◽
Komal Jhaveri
◽
Kevin Kalinsky
◽
Sibylle Loibl
◽
Sherene Loi
◽
...
Close
Export Citation Format
Close
Share Document
Close